Overview of polar exhibit tanks and List of the creatures in house

The Tenth Symposium on Polar Science/Ordinary sessions : [OB] Polar Biology, Wed. 4 Dec. / Entrance Hall (1st floor) , National Institute of Polar Researc

Comparison of Vegetation Indices and Spectral Reflectance Observed by Two Types of UAV-mounted Multispectral Camera

departmental bulletin pape

Effects of Cultivation Methods on Paddy Rice Growth Observed by UAV-mounted Multispectral Camera

departmental bulletin pape

Subaru/MOIRCS Near-Infrared Imaging in the Proto-Cluster Region at z=3.1

We present the results of deep near-infrared imaging observations of the z=3.1 proto-cluster region in the SSA22a field taken by MOIRCS mounted on the Subaru Telescope. We observed a 21.7 arcmin^2 field to the depths of J=24.5, H=24.3, and K=23.9 (5 sigma). We examine the distribution of the K-selected galaxies at z~3 by using the simple color cut for distant red galaxies (DRGs) as well as the photometric-redshift selection technique. The marginal density excess of DRGs and the photo-z selected objects are found around the two most luminous Ly alpha blobs (LABs). We investigate the correlation between the K-selected objects and the LABs, and find that several galaxies with stellar mass M_* = 10^9-10^11 M_solar exist in vicinity of LABs, especially around the two most luminous ones. We also find that 7 of the 8 LABs in the field have plausible K_s-band counterparts and the sum of the stellar mass possibly associated with LABs correlates with the luminosity and surface brightness of them, which implies that the origin of Ly alpha emission may be closely correlated with their stellar mass or their previous star formation phenomena.Comment: 15 pages, 9 figures, accepted for publication in PASJ Vol.60, No.

Forgeability of AZ Series Magnesium Alloy produced by Twin Roll Casting

Plastic forming of magnesium alloy is hardly reported because of its low forgeability. The productions of magnesium alloy are mainly produced by casting. Typical wrought magnesium alloy is AZ31. Magnesium-aluminum alloy indicates maximum elongation when the composition includes 3% aluminum. When the magnesium alloy includes over 3% aluminum, its elongation slightly decreases. Therefore, AZ31 that include 3% aluminum and 1% zinc is generally used for plastic forming. The more increasing aluminum composition, the larger 0.2% proof stress becomes. However its forgeability is decreasing because of precipitation of β phase such as Mg17Al12. It is supposed that the β phase is refined by rapid cooling casting process such as twin roll casting. In this paper, the magnesium alloy thick sheet of AZ91, AZ121 and AZ131 for hot forging, that include 9%, 12% and 13% aluminum composition respectively, was produced by twin roll strip casting process. And the forgeability of high aluminum containing magnesium alloy was investigated by die forging. As a result, it was possible to forge their magnesium alloys

Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush

Common dermatological side-effects associated with erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), include pruritus and skin rash, which are mediated by substance P, leading to the occasional discontinuation of cancer treatment. Aprepitant is an antagonist of neurokinin-1 receptor, through which substance P activates the pruritogens. Thus, aprepitant is expected to offer a promising option for the treatment of erlotinib-induced pruritus. However, the appropriate treatment schedule for aprepitant administration is under consideration. Here, we discuss the need for flexible adjustment of the treatment schedule for aprepitant administration against erlotinib-induced refractory pruritus and skin rush. A 71-year-old female smoker presented with stage IV EGFR-mutated lung adenocarcinoma. She was started on erlotinib at 150 mg/day. However, by 28 days, severe pruritus and acneiform skin rush resistant to standard therapies occurred, resulting in the interruption of erlotinib therapy. After recovery, she was restarted on erlotinib at 100 mg/day. However, severe pruritus and skin rush developed again within 2 weeks. Then, we started the first 3-day dose of aprepitant (125 mg on day 1, 80 mg on day 3, and 80 mg on day 5) based on the results of the previous prospective study, which showed the success rate of 100% with at least the second dose of aprepitant. However, the pruritus and skin rush exacerbated again within 4 weeks. Therefore, we started the second 3-day dose of aprepitant, but in vain. At this point, as the patient-centered medicine, bi-weekly schedule of the 3-day dose of aprepitant was considered and, then, adopted. As the results, the pruritus and skin rush remained well-controlled throughout the subsequent treatment with erlotinib